Abstract
Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.
Keywords: Pediatric inflammatory bowel disease, juvenile rheumatoid arthritis, personalized therapy, pharmacogenetics, pharmacokinetics, pharmacodynamics
Current Pharmaceutical Design
Title:Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Volume: 18 Issue: 35
Author(s): Gabriele Stocco, Sara De Iudicibus, Raffaella Franca, Riccardo Addobbati and Giuliana Decorti
Affiliation:
Keywords: Pediatric inflammatory bowel disease, juvenile rheumatoid arthritis, personalized therapy, pharmacogenetics, pharmacokinetics, pharmacodynamics
Abstract: Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.
Export Options
About this article
Cite this article as:
Stocco Gabriele, De Iudicibus Sara, Franca Raffaella, Addobbati Riccardo and Decorti Giuliana, Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530853
DOI https://dx.doi.org/10.2174/138161212803530853 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms Leading to Autoantibody Production: Link Between Inflammation and Autoimmunity
Current Drug Targets - Inflammation & Allergy Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design VEGFR1 Signaling Regulates IL-4-Mediated Arginase 1 Expression in Macrophages
Current Molecular Medicine Associations between Depressive Disorders and Inflammatory Rheumatic Diseases
Current Topics in Medicinal Chemistry Nanocarriers as Tools in Delivering Active Compounds for Immune System Related Pathologies
Recent Patents on Nanotechnology Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry Recent Developments of 2–Substituted Analogs of 1,25(OH)<sub>2</sub>D<sub>3</sub>
Current Medicinal Chemistry Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine Blood Brain Barrier Compromise with Endothelial Inflammation may Lead to Autoimmune Loss of Myelin during Multiple Sclerosis
Current Neurovascular Research Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) B-Cell Based Gene Therapy for Inducing Tolerance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry